Abstract:Abstract Objective The purpose of this study was to explore the effect of CRABP2 and FABP5, and their ratio on prognosis in esophageal squamous cell carcinoma. Methods The expression data of CRABP2 in esophageal cancer in TCGA and GEO were collected by the public database GEPIA. The expression levels of CRABP2 and FABP5 were examined using immunohistochemistry. The relationship between the two proteins and related clinicopathological parameters were analyzed by χ 2 test. Survival analysis was used to investigate the effect of CRABP2 and FABP5, and their ratio on prognosis. Results Compared with normal esophageal mucosal epithelium, there was lower CRABP2 gene mRNA in the esophageal cancer tissue, and the difference was statistically significant ( p < 0.01). For the expression level, no significant difference was observed in patients with stages I–IV in esophageal cancer. Immunohistochemistry showed that CRABP2 and FABP5 were both highly expressed in normal esophageal squamous epithelial cells at 100 and 94.1%, while lower in ESCC (75.6 and 58.7%). There was a significant difference in the expression between cancer and adjacent tissues ( p < 0.001). No inherent relationship was manifested between the CRABP2 expression and the clinical parameters of the ESCC. The expression of FABP5 was related to lymph node metastasis ( p = 0.032), the depth of invasion ( p = 0.041), and the AJCC stage ( p = 0.013). The ratio of CRABP2 and FABP5 was related to ethnicity ( p = 0.001), nerve invasion ( p = 0.031), and postoperative treatment ( p = 0.038). CRABP2 is positively associated with FABP5 ( r = 0.156, p = 0.041) and the ratio ( r = 0.334, p = 0.000), while there was a negative correlation between FABP5 and the ratio ( r = −0.269, p = 0.000). Patients with CRABP2-positive expression had a significantly longer overall survival than patients with CRABP2-negative expression ( p = 0.025). Conclusion CRABP2 as a suppressor factor is expected to be a potential prognosis marker for esophageal squamous cell carcinoma.

High FABP5 Versus CRABPII Expression Ratio in Recurrent Craniopharyngiomas: Implications for Future Treatment.

All-Trans Retinoic Acid Inhibits Craniopharyngioma Cell Growth: Study on an Explant Cell Model

Recurrent Prognostic Factors And Expression Of Glut-1, Pi3k And P-Akt In Adenoid Cystic Carcinomas Of The Head And Neck: Clinicopathological Features And Biomarkers Of Adenoid Cystic Carcinoma

CRABP-II- and FABP5-independent all-trans retinoic acid resistance in COLO 16 human cutaneous squamous cancer cells.

Relative Quantitative Expression Of Hypoxia-Inducible Factor 1 Alpha Messenger Ribonucleic Acid In Recurrent Craniopharyngiomas

CRABP-II- and FABP5-independent responsiveness of human glioblastoma cells to all-trans retinoic acid.

Overexpression Levels of Cripto-1 Predict Poor Prognosis in Patients with Prostate Cancer Following Radical Prostatectomy

Expression and function analysis of CRABP2 and FABP5, and their ratio in esophageal squamous cell carcinoma

High Expression Levels of CXCL12 and CXCR4 Predict Recurrence of Adamanti-Nomatous Craniopharyngiomas in Children

Proteomics study of primary and recurrent adamantinomatous craniopharyngiomas

Prognostic value of preoperative absolute lymphocyte count in recurrent hepatocellular carcinoma following thermal ablation: a retrospective analysis.

Differential CRABP-II and FABP5 expression patterns and implications for medulloblastoma retinoic acid sensitivity

The cell-cycle kinetics of craniopharyngioma and its clinical significance

Craniopharyngioma cell growth is promoted by growth hormone (GH) and is inhibited by tamoxifen: involvement of growth hormone receptor (GHR) and IGF-1 receptor (IGF-1R).

Expression of human MCM6 and DNA Topo II alpha in craniopharyngiomas and its correlation with recurrence of the tumor.

Expression of Matrix Metalloproteinase-9, Type IV Collagen and Vascular Endothelial Growth Factor in Adamantinous Craniopharyngioma

Expression of Human MCM6 and DNA Topo II α in craniopharyngiomas and its correlation with recurrence of the tumor

Expression of Interferon-Α Receptor and Proliferating Cell Nuclear Antigen in Craniopharyngioma

Expression of Integrin Αvβ3 in Craniopharyngioma and Its Correlation with Prognosis

Effect of CRABP2 on lung cancer cells in response to all-trans retinoic acid and cell proliferation

Research on the correlativity of expressions of CXCL12 and CXCR4 with the invasiveness and recurrence of adamantimous craniopharyngiomas